|         |                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------|
| • | Reported net sales totaled $1.4 billion, up 2.1 percent. Sales grew 4.1 percent in constant currency. |

|         |                                                                                           |
|---------|-------------------------------------------------------------------------------------------|
| • | GAAP earnings from continuing operations increased 12 percent to $0.48 per diluted share. |

|         |                                                                                         |
|---------|-----------------------------------------------------------------------------------------|
| • | Adjusted earnings from continuing operations1 were flat at $0.56 per diluted share. |

|         |                                                                                                                                                                                                              |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Company elects not to extend the exclusive portion of its Sirona relationship after September 2017, but intends to remain a strategic partner and continue offering the full Sirona product line thereafter. |

|         |                                                                                                                           |
|---------|---------------------------------------------------------------------------------------------------------------------------|
| • | Company revises Fiscal 2017 outlook and expects non-GAAP earnings to be in the range of $2.25 to $2.35 per diluted share. |

----

|         |                                                  |
|---------|--------------------------------------------------|
| • | Consumable dental supplies decreased 2.5 percent |

|         |                                                                                                                  |
|---------|------------------------------------------------------------------------------------------------------------------|
| • | Equipment sales improved 4.2 percent, led by double-digit increases in core equipment and digital x-ray products |

|         |                                                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Other services and products, primarily composed of technical service, parts and labor, software support services and office supplies, rose 0.2 percent |

----

----

|         |                                                                                                    |
|---------|----------------------------------------------------------------------------------------------------|
| • | GAAP earnings are expected to be in the range of $1.65 to $1.75 per diluted share for fiscal 2017. |

|         |                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------|
| • | Non-GAAP adjusted earnings for fiscal 2017 are now expected to be in the range of $2.25 to $2.35 per diluted share. |

|         |                                                                           |
|---------|---------------------------------------------------------------------------|
| • | Our non-GAAP adjusted earnings guidance excludes the after-tax impact of: |

|         |                                                                                  |
|---------|----------------------------------------------------------------------------------|
| ◦ | Deal amortization expense of approximately $27 million ($0.28 per diluted share) |

|         |                                                                                    |
|---------|------------------------------------------------------------------------------------|
| ◦ | Non-cash impairment charges of approximately $22 million ($0.23 per diluted share) |

|         |                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------|
| ◦ | Integration and business restructuring expenses of approximately $6 million ($0.06 per diluted share) |

|         |                                                                                 |
|---------|---------------------------------------------------------------------------------|
| ◦ | Transaction-related costs of approximately $3 million ($0.03 per diluted share) |

----

----

|                                                                                                               |
|---------------------------------------------------------------------------------------------------------------|
|                                                                                                               |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                                          | Three Months Ended |   | Six Months Ended |
|                                                                                                          | October 29, 2016 |   | October 31, 2015 |   | October 29, 2016 |   | October 31, 2015 |
|                                                                                                          |   |   |   |   |   |   |   |
| Net sales                                                                                                     | $ | 1,418,241 |  |   | $ | 1,389,210 |  |   | $ | 2,750,677 |  |   | $ | 2,532,080 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Gross profit                                                                                                  | 318,960 |  |   | 330,899 |  |   | 636,138 |  |   | 619,143 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Operating expenses                                                                                            | 239,157 |  |   | 247,436 |  |   | 490,919 |  |   | 473,503 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Operating income from continuing operations                                                                   | 79,803 |  |   | 83,463 |  |   | 145,219 |  |   | 145,640 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Other income and expense:                                                                                     |   |   |   |   |   |   |   |
| Other income, net                                                                                             | 1,622 |  |   | 954 |  |   | 3,986 |  |   | 1,624 |  |
| Interest expense                                                                                              | (10,097 | ) |   | (17,154 | ) |   | (20,259 | ) |   | (29,297 | ) |
|                                                                                                          |   |   |   |   |   |   |   |
| Income from continuing operations before taxes                                                                | 71,328 |  |   | 67,263 |  |   | 128,946 |  |   | 117,967 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Income tax expense                                                                                            | 25,572 |  |   | 24,700 |  |   | 44,284 |  |   | 55,093 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Net income from continuing operations                                                                         | 45,756 |  |   | 42,563 |  |   | 84,662 |  |   | 62,874 |  |
| Net income (loss) from discontinued operations                                                                | — |  |   | (7,142 | ) |   | — |  |   | 2,250 |  |
| Net income                                                                                                    | $ | 45,756 |  |   | $ | 35,421 |  |   | $ | 84,662 |  |   | $ | 65,124 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Basic earnings (loss) per share:                                                                              |   |   |   |   |   |   |   |
| Continuing operations                                                                                         | $ | 0.48 |  |   | $ | 0.43 |  |   | $ | 0.89 |  |   | $ | 0.64 |  |
| Discontinued operations                                                                                       | — |  |   | (0.07 | ) |   | — |  |   | 0.02 |  |
|             Net basic earnings (loss) per share   | $ | 0.48 |  |   | $ | 0.36 |  |   | $ | 0.89 |  |   | $ | 0.66 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Diluted earnings (loss) per share:                                                                            |   |   |   |   |   |   |   |
| Continuing operations                                                                                         | $ | 0.48 |  |   | $ | 0.43 |  |   | $ | 0.88 |  |   | $ | 0.63 |  |
| Discontinued operations                                                                                       | — |  |   | (0.07 | ) |   | — |  |   | 0.02 |  |
|             Net diluted earnings (loss) per share | $ | 0.48 |  |   | $ | 0.36 |  |   | $ | 0.88 |  |   | $ | 0.65 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Shares:                                                                                                       |   |   |   |   |   |   |   |
|    Basic                                                                                       | 95,290 |  |   | 98,525 |  |   | 95,510 |  |   | 98,981 |  |
|    Diluted                                                                                     | 95,904 |  |   | 99,185 |  |   | 96,138 |  |   | 99,674 |  |
|                                                                                                          |   |   |   |   |   |   |   |
| Dividends declared per common share                                                                           | $ | 0.24 |  |   | $ | 0.22 |  |   | $ | 0.48 |  |   | $ | 0.44 |  |

----

|                                                                                                              |
|--------------------------------------------------------------------------------------------------------------|
|                                                                                                              |  |  |  |  |  |  |  |
|                                                                                                         | October 29, 2016 |   | April 30, 2016 |
|                                                                                                         | (Unaudited) |   |   |
| ASSETS                                                                                                       |   |   |   |
| Current assets:                                                                                              |   |   |   |
| Cash and cash equivalents                                                                                    | $ | 110,387 |  |   | $ | 137,453 |  |
| Receivables                                                                                                  | 822,734 |  |   | 796,693 |  |
| Inventory                                                                                                    | 795,454 |  |   | 722,140 |  |
| Prepaid expenses and other current assets                                                                    | 104,257 |  |   | 91,255 |  |
|            Total current assets                       | 1,832,832 |  |   | 1,747,541 |  |
| Property and equipment, net                                                                                  | 303,342 |  |   | 293,315 |  |
| Goodwill and other intangible assets                                                                         | 1,292,396 |  |   | 1,325,889 |  |
| Long-term receivables, net and other                                                                         | 161,798 |  |   | 154,059 |  |
|            Total assets                               | $ | 3,590,368 |  |   | $ | 3,520,804 |  |
|                                                                                                         |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                         |   |   |   |
| Current liabilities:                                                                                         |   |   |   |
| Accounts payable                                                                                             | $ | 545,366 |  |   | $ | 566,253 |  |
| Other accrued liabilities                                                                                    | 217,678 |  |   | 226,582 |  |
| Current maturities of long-term debt                                                                         | 20,625 |  |   | 16,500 |  |
| Borrowings on revolving credit                                                                               | 163,000 |  |   | 20,000 |  |
|            Total current liabilities                  | 946,669 |  |   | 829,335 |  |
| Long-term debt                                                                                               | 1,010,211 |  |   | 1,022,155 |  |
| Other non-current liabilities                                                                                | 227,436 |  |   | 227,568 |  |
|            Total liabilities                          | 2,184,316 |  |   | 2,079,058 |  |
| Stockholders' equity                                                                                         | 1,406,052 |  |   | 1,441,746 |  |
|            Total liabilities and stockholders' equity | $ | 3,590,368 |  |   | $ | 3,520,804 |  |

----

|                                                                                                                 |
|-----------------------------------------------------------------------------------------------------------------|
|                                                                                                                 |  |  |  |  |  |  |  |
|                                                                                                                 | Six Months Ended |
|                                                                                                                 | October 29, 2016 |  | October 31, 2015 |
|                                                                                                                 |  |  |  |
| Operating activities:                                                                                           |  |  |  |
| Net income                                                                                                      | $ | 84,662 |  |  | $ | 65,124 |  |
| Net income from discontinued operations                                                                         | — |  |  | 2,250 |  |
| Net income from continuing operations                                                                           | 84,662 |  |  | 62,874 |  |
| Adjustments to reconcile net income from continuing operations        to net cash used in operating activities: |  |  |  |
|       Depreciation and amortization                                               | 42,007 |  |  | 38,400 |  |
|       Non-cash employee compensation                                              | 14,693 |  |  | 13,541 |  |
|       Change in assets and liabilities, net of acquired                           | (196,668 | ) |  | (128,782 | ) |
| Net cash used in operating activities - continuing operations                                                   | (55,306 | ) |  | (13,967 | ) |
| Net cash used in operating activities - discontinued operations                                                 | — |  |  | (38,985 | ) |
| Net cash used in operating activities                                                                           | (55,306 | ) |  | (52,952 | ) |
| Investing activities:                                                                                           |  |  |  |
|    Additions to property and equipment, net of disposals                                         | (29,377 | ) |  | (40,978 | ) |
|    Acquisitions and equity investments                                                           | — |  |  | (1,105,229 | ) |
|    Proceeds from sale of securities                                                              | — |  |  | 48,744 |  |
|    Other investing activities                                                                    | 23,115 |  |  | — |  |
| Net cash used in investing activities - continuing operations                                                   | (6,262 | ) |  | (1,097,463 | ) |
| Net cash provided by investing activities - discontinued operations                                             | — |  |  | 715,430 |  |
| Net cash used in investing activities                                                                           | (6,262 | ) |  | (382,033 | ) |
| Financing activities:                                                                                           |  |  |  |
|    Dividends paid                                                                                | (47,655 | ) |  | (45,356 | ) |
|    Repurchases of common stock                                                                   | (50,000 | ) |  | (160,579 | ) |
|    Proceeds from issuance of long-term debt, net                                                 | — |  |  | 988,400 |  |
|    Retirement of long-term debt                                                                  | (8,250 | ) |  | (674,125 | ) |
|    Draw on revolver                                                                              | 143,000 |  |  | 80,000 |  |
|    Other financing activities                                                                    | 974 |  |  | 2,894 |  |
| Net cash provided by financing activities                                                                       | 38,069 |  |  | 191,234 |  |
| Effect of exchange rate changes on cash                                                                         | (3,567 | ) |  | (8,058 | ) |
| Net change in cash and cash equivalents                                                                         | $ | (27,066 | ) |  | $ | (251,809 | ) |

----

|                        |
|------------------------|
|                        |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                   | October 29, 2016 |   | October 31, 2015 |   | TotalSalesGrowth |   | ForeignExchangeImpact |   | Animal HealthInternationalImpact |   | InternalGrowth |
| Three Months Ended     |   |   |   |   |   |   |   |   |   |   |   |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated net sales |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 1,112,232 |  |   | $ | 1,087,489 |  |   | 2.3 |  % |   | (2.5 | )% |   | — |  % |   | 4.8 |  % |
| Equipment and software | 217,194 |  |   | 207,809 |  |   | 4.5 |  |   | — |  |   | — |  |   | 4.5 |  |
| Other                  | 88,815 |  |   | 93,912 |  |   | (5.4 | ) |   | (0.9 | ) |   | — |  |   | (4.5 | ) |
| Total                  | $ | 1,418,241 |  |   | $ | 1,389,210 |  |   | 2.1 |  % |   | (2.0 | )% |   | — |  % |   | 4.1 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Dental                 |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 324,237 |  |   | $ | 332,436 |  |   | (2.5 | )% |   | — |  % |   | — |  % |   | (2.5 | )% |
| Equipment and software | 205,062 |  |   | 196,767 |  |   | 4.2 |  |   | — |  |   | — |  |   | 4.2 |  |
| Other                  | 72,254 |  |   | 72,119 |  |   | 0.2 |  |   | — |  |   | — |  |   | 0.2 |  |
| Total                  | $ | 601,553 |  |   | $ | 601,322 |  |   | — |  % |   | — |  % |   | — |  % |   | — |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Animal Health          |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 787,995 |  |   | $ | 755,053 |  |   | 4.4 |  % |   | (3.6 | )% |   | — |  % |   | 8.0 |  % |
| Equipment and software | 12,132 |  |   | 11,042 |  |   | 9.9 |  |   | (0.3 | ) |   | — |  |   | 10.2 |  |
| Other                  | 7,019 |  |   | 8,358 |  |   | (16.0 | ) |   | (9.9 | ) |   | — |  |   | (6.1 | ) |
| Total                  | $ | 807,146 |  |   | $ | 774,453 |  |   | 4.2 |  % |   | (3.6 | )% |   | — |  % |   | 7.8 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Corporate              |   |   |   |   |   |   |   |   |   |   |   |
| Other                  | $ | 9,542 |  |   | $ | 13,435 |  |   | (29.0 | )% |   | — |  % |   | — |  % |   | (29.0 | )% |
| Total                  | $ | 9,542 |  |   | $ | 13,435 |  |   | (29.0 | )% |   | — |  % |   | — |  % |   | (29.0 | )% |
|                   |   |   |   |   |   |   |   |   |   |   |   |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Six Months Ended       |   |   |   |   |   |   |   |   |   |   |   |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated net sales |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 2,188,453 |  |   | $ | 1,982,796 |  |   | 10.4 |  % |   | (2.3 | )% |   | 9.8 |  % |   | 2.9 |  % |
| Equipment and software | 378,140 |  |   | 361,292 |  |   | 4.7 |  |   | (0.2 | ) |   | — |  |   | 4.9 |  |
| Other                  | 184,084 |  |   | 187,992 |  |   | (2.1 | ) |   | (0.8 | ) |   | (0.1 | ) |   | (1.2 | ) |
| Total                  | $ | 2,750,677 |  |   | $ | 2,532,080 |  |   | 8.6 |  % |   | (1.9 | )% |   | 7.7 |  % |   | 2.8 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Dental                 |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 657,185 |  |   | $ | 690,488 |  |   | (4.8 | )% |   | (0.2 | )% |   | — |  % |   | (4.6 | )% |
| Equipment and software | 355,944 |  |   | 340,437 |  |   | 4.6 |  |   | (0.2 | ) |   | — |  |   | 4.8 |  |
| Other                  | 143,439 |  |   | 145,514 |  |   | (1.4 | ) |   | (0.1 | ) |   | — |  |   | (1.3 | ) |
| Total                  | $ | 1,156,568 |  |   | $ | 1,176,439 |  |   | (1.7 | )% |   | (0.2 | )% |   | — |  % |   | (1.5 | )% |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Animal Health          |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 1,531,268 |  |   | $ | 1,292,308 |  |   | 18.5 |  % |   | (3.4 | )% |   | 15.0 |  % |   | 6.9 |  % |
| Equipment and software | 22,196 |  |   | 20,855 |  |   | 6.4 |  |   | (0.2 | ) |   | — |  |   | 6.6 |  |
| Other                  | 16,313 |  |   | 18,587 |  |   | (12.2 | ) |   | (7.0 | ) |   | (0.9 | ) |   | (4.3 | ) |
| Total                  | $ | 1,569,777 |  |   | $ | 1,331,750 |  |   | 17.9 |  % |   | (3.4 | )% |   | 14.6 |  % |   | 6.7 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Corporate              |   |   |   |   |   |   |   |   |   |   |   |
| Other                  | $ | 24,332 |  |   | $ | 23,891 |  |   | 1.8 |  % |   | — |  % |   | — |  % |   | 1.8 |  % |
| Total                  | $ | 24,332 |  |   | $ | 23,891 |  |   | 1.8 |  % |   | — |  % |   | — |  % |   | 1.8 |  % |

----

|                         |
|-------------------------|
|                         |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                    | Three Months Ended |   | Six Months Ended |
|                    | October 29, 2016 |   | October 31, 2015 |   | October 29, 2016 |   | October 31, 2015 |
|                    |   |   |   |   |   |   |   |
| Operating income (loss) |   |   |   |   |   |   |   |
| Dental                  | $ | 77,043 |  |   | $ | 74,094 |  |   | $ | 137,338 |  |   | $ | 141,346 |  |
| Animal Health           | 21,854 |  |   | 25,177 |  |   | 36,683 |  |   | 38,149 |  |
| Corporate               | (19,094 | ) |   | (15,808 | ) |   | (28,802 | ) |   | (33,855 | ) |
| Total                   | $ | 79,803 |  |   | $ | 83,463 |  |   | $ | 145,219 |  |   | $ | 145,640 |  |

----

|                                                |
|------------------------------------------------|
|                                                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| For the three months ended October 29, 2016    |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Tax impact of cash repatriation |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 79,803 |  |   | $ | 896 |  |   | $ | 10,247 |  |   | $ | 804 |  |   | $ | — |  |   | $ | — |  |   | $ | 91,750 |  |
| Other expense, net                             |   | (8,475 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | (8,475 | ) |
| Income from continuing operations before taxes |   | 71,328 |  |   | 896 |  |   | 10,247 |  |   | 804 |  |   | — |  |   | — |  |   | 83,275 |  |
| Income tax expense                             |   | 25,572 |  |   | 338 |  |   | 3,537 |  |   | 304 |  |   | — |  |   | — |  |   | 29,751 |  |
| Net income from continuing operations          |   | $ | 45,756 |  |   | $ | 558 |  |   | $ | 6,710 |  |   | $ | 500 |  |   | $ | — |  |   | $ | — |  |   | $ | 53,524 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 0.48 |  |   | $ | 0.01 |  |   | $ | 0.07 |  |   | $ | 0.01 |  |   | $ | — |  |   | $ | — |  |   | $ | 0.56 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 5.6 | % |   |   |   |   |   |   |   |   |   |   |   | 6.5 | % |
| Effective tax rate                             |   | 35.9 | % |   |   |   |   |   |   |   |   |   |   |   | 35.7 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| For the three months ended October 31, 2015    |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Tax impact of cash repatriation |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 83,463 |  |   | $ | 723 |  |   | $ | 10,862 |  |   | $ | 2,183 |  |   | $ | — |  |   | $ | — |  |   | $ | 97,231 |  |
| Other expense, net                             |   | (16,200 | ) |   | — |  |   | — |  |   | — |  |   | 5,153 |  |   | — |  |   | (11,047 | ) |
| Income from continuing operations before taxes |   | 67,263 |  |   | 723 |  |   | 10,862 |  |   | 2,183 |  |   | 5,153 |  |   | — |  |   | 86,184 |  |
| Income tax expense                             |   | 24,700 |  |   | 46 |  |   | 3,888 |  |   | 825 |  |   | 1,948 |  |   | (500 | ) |   | 30,907 |  |
| Net income from continuing operations          |   | $ | 42,563 |  |   | $ | 677 |  |   | $ | 6,974 |  |   | $ | 1,358 |  |   | $ | 3,205 |  |   | $ | 500 |  |   | $ | 55,277 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 0.43 |  |   | $ | 0.01 |  |   | $ | 0.07 |  |   | $ | 0.01 |  |   | $ | 0.03 |  |   | $ | 0.01 |  |   | $ | 0.56 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 6.0 | % |   |   |   |   |   |   |   |   |   |   |   | 7.0 | % |
| Effective tax rate                             |   | 36.7 | % |   |   |   |   |   |   |   |   |   |   |   | 35.9 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| For the six months ended October 29, 2016      |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Tax impact of cash repatriation |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 145,219 |  |   | $ | 1,243 |  |   | $ | 20,261 |  |   | $ | 5,679 |  |   | $ | — |  |   | $ | — |  |   | $ | 172,402 |  |
| Other expense, net                             |   | (16,273 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | (16,273 | ) |
| Income from continuing operations before taxes |   | 128,946 |  |   | 1,243 |  |   | 20,261 |  |   | 5,679 |  |   | — |  |   | — |  |   | 156,129 |  |
| Income tax expense                             |   | 44,284 |  |   | 469 |  |   | 6,914 |  |   | 2,147 |  |   | — |  |   | — |  |   | 53,814 |  |
| Net income from continuing operations          |   | $ | 84,662 |  |   | $ | 774 |  |   | $ | 13,347 |  |   | $ | 3,532 |  |   | $ | — |  |   | $ | — |  |   | $ | 102,315 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 0.88 |  |   | $ | 0.01 |  |   | $ | 0.14 |  |   | $ | 0.04 |  |   | $ | — |  |   | $ | — |  |   | $ | 1.06 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 5.3 | % |   |   |   |   |   |   |   |   |   |   |   | 6.3 | % |
| Effective tax rate                             |   | 34.3 | % |   |   |   |   |   |   |   |   |   |   |   | 34.5 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| For the six months ended October 31, 2015      |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Tax impact of cash repatriation |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 145,640 |  |   | $ | 13,088 |  |   | $ | 17,896 |  |   | $ | 3,583 |  |   | $ | — |  |   | $ | — |  |   | $ | 180,207 |  |
| Other expense, net                             |   | (27,673 | ) |   | — |  |   | — |  |   | — |  |   | 5,153 |  |   | — |  |   | (22,520 | ) |
| Income from continuing operations before taxes |   | 117,967 |  |   | 13,088 |  |   | 17,896 |  |   | 3,583 |  |   | 5,153 |  |   | — |  |   | 157,687 |  |
| Income tax expense                             |   | 55,093 |  |   | 3,109 |  |   | 6,310 |  |   | 1,354 |  |   | 1,948 |  |   | (12,300 | ) |   | 55,514 |  |
| Net income from continuing operations          |   | $ | 62,874 |  |   | $ | 9,979 |  |   | $ | 11,586 |  |   | $ | 2,229 |  |   | $ | 3,205 |  |   | $ | 12,300 |  |   | $ | 102,173 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 0.63 |  |   | $ | 0.10 |  |   | $ | 0.12 |  |   | $ | 0.02 |  |   | $ | 0.03 |  |   | $ | 0.12 |  |   | $ | 1.03 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 5.8 | % |   |   |   |   |   |   |   |   |   |   |   | 7.1 | % |
| Effective tax rate                             |   | 46.7 | % |   |   |   |   |   |   |   |   |   |   |   | 35.2 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| * May not sum due to rounding                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |